Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-9810 ________________ ...

Owens & Minor, Inc. (NYSE:OMI) Q3 2022 Earnings Conference Call November 2, 2022 8:30 AM ET Corporate Participants Alex Jost - Director-Investor Relations Ed Pesicka - President and Chief Executive Officer Alex Bruni - Executive Vice President and Chief Financial Officer Conference Call Participants Andrea Alfonso - UBS Daniel Grosslight - Citi John Stansel - JPMorgan Charlotte Kolb - Bank of America Operator Good day and thank you for standing by. Welcome to Owens & Minor’s Third Quarter 2022 Earnings Conf ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-9810 _____________________ ...

2022 Company Outlook - The company projects full year 2022 revenue to be in the range of $9.8 billion to $10.1 billion[3] - The company anticipates a gross margin of approximately 20% for the full year 2022[3] - The company expects interest expense to be between $130 million and $135 million for the full year 2022[3] - The company forecasts capital expenditures to be in the range of $185 million to $195 million for the full year 2022[3] - The company estimates an adjusted effective tax rate between 24% and 26% for the full year 2022[3] - The company anticipates approximately 77 million diluted weighted average shares outstanding[3] - The company projects adjusted EBITDA to be in the range of $570 million to $610 million for the full year 2022[3] - The company expects adjusted EPS to be in the range of $2.85 to $3.15 for the full year 2022[3] External Factors - The company notes that commodity prices, inflation, and interest rates are unfavorable in the near-term[3] - The company states that foreign currency rates are as of June 30, 2022[3]

Owens & Minor, Inc. (NYSE:OMI) Q2 2022 Earnings Conference Call August 3, 2022 8:00 AM ET Company Participants Alex Jost – Director-Investor Relations Ed Pesicka – President and Chief Executive Officer Andy Long – Executive Vice President and Chief Financial Officer Conference Call Participants Kevin Caliendo – UBS Daniel Grosslight – Citi Hannah Lee – Bank of America Eric Coldwell – Robert W. Baird Operator Good day, and thank you for standing by. Welcome to Owens & Minor’s Second Quarter 2022 Financial Re ...

Financial Outlook for 2022 - Revenue is projected to be in the range of $9.9 billion to $10.3 billion[8] - Gross margin is expected to be approximately 20%[8] - Interest expense is estimated to be between $125 million and $130 million[8] - Capital expenditures are projected to be in the range of $175 million to $185 million[8] - The adjusted effective tax rate is expected to be between 24% and 26%[8] - Adjusted EBITDA is projected to be in the range of $580 million to $630 million[8] - Adjusted EPS is expected to be between $3.05 and $3.55[8] Other Considerations - The company anticipates unfavorable conditions in the near term regarding commodity prices, inflation, and interest rates[8] - The company's outlook and modeling assumptions are used for 2022 adjusted EPS guidance, and the company undertakes no obligation to update such assumptions subsequent to the date of this presentation[8] - The presentation includes combined financial information for the Company and Apria without adjustments, which does not comply with U.S GAAP or pro forma presentation rules[5] - The company uses non-GAAP financial measures internally to evaluate performance, balance sheet, financial and operational planning and determine incentive compensation[7]

Owens & Minor, Inc. (NYSE:OMI) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Ed Pesicka - President and Chief Executive Officer Andy Long - Executive Vice President and Chief Financial Officer Alex Jost - CPA Director, Investor Relations Conference Call Participants Michael Cherny - Bank of America Merrill Lynch A.J. Rice - Credit Suisse Kevin Caliendo - UBS Daniel Grosslight - Citi Eric Coldwell - Baird Michael Minchak - JPMorgan Operator Good day and thank you for standing ...

Part I [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited consolidated financial statements, including operations, balance sheets, cash flows, and notes on the Apria acquisition and segment reorganization [Consolidated Statements of Operations](index=3&type=section&id=Consolidated%20Statements%20of%20Operations) Net revenue increased 3.5% to $2.41 billion in Q1 2022, but gross margin, operating income, and net income significantly declined, with diluted EPS dropping to $0.52 Consolidated Statements of Operations (Q1 2022 vs Q1 2021) | Metric | Q1 2022 (in thousands) | Q1 2021 (in thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Net revenue | $2,406,952 | $2,326,534 | 3.5% | | Gross margin | $373,448 | $442,751 | (15.7)% | | Operating income | $61,059 | $146,692 | (58.4)% | | Net income | $39,279 | $69,589 | (43.6)% | | Diluted EPS | $0.52 | $0.98 | (46.9)% | [Consolidated Balance Sheets](index=5&type=section&id=Consolidated%20Balance%20Sheets) Total assets significantly increased to $5.71 billion by March 31, 2022, primarily due to the Apria acquisition, which also drove a sharp rise in total liabilities to $4.76 billion Consolidated Balance Sheet Highlights | Metric (in thousands) | March 31, 2022 | December 31, 2021 | | :--- | :--- | :--- | | Total current assets | $2,553,349 | $2,321,812 | | Goodwill | $1,657,159 | $390,185 | | Total assets | $5,707,969 | $3,536,551 | | Total current liabilities | $1,654,295 | $1,344,021 | | Long-term debt | $2,635,314 | $947,540 | | Total liabilities | $4,760,347 | $2,598,050 | | Total equity | $947,622 | $938,501 | [Consolidated Statements of Cash Flows](index=6&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Operating cash flow significantly improved to $79.7 million in Q1 2022, while investing activities used $1.59 billion for the Apria acquisition, largely funded by $1.66 billion from financing activities Cash Flow Summary (Three Months Ended March 31) | Activity (in thousands) | 2022 | 2021 | | :--- | :--- | :--- | | Cash provided by operating activities | $79,699 | $25,423 | | Cash used for investing activities | $(1,587,236) | $(6,619) | | Cash provided by (used for) financing activities | $1,664,194 | $(80,394) | | Net increase (decrease) in cash | $155,988 | $(63,729) | - The primary use of cash in investing activities was the acquisition of Apria, net of cash acquired, for **$1.58 billion**[16](index=16&type=chunk) - The company raised **$1.69 billion** from the issuance of new debt to fund the acquisition and other corporate purposes[16](index=16&type=chunk) [Notes to Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) The notes detail accounting policies, the company's reorganization into Products & Healthcare Services and Patient Direct segments, the **$1.7 billion** Apria acquisition, and specifics on goodwill, debt, and segment performance - The company reorganized its business into two new segments: **Products & Healthcare Services** and **Patient Direct**, effective Q1 2022[22](index=22&type=chunk)[76](index=76&type=chunk) - On March 29, 2022, the company acquired 100% of Apria, Inc. for approximately **$1.7 billion**, adding **$1.27 billion** to goodwill, assigned to the Patient Direct segment[23](index=23&type=chunk)[31](index=31&type=chunk)[34](index=34&type=chunk) - To fund the Apria acquisition, the company issued **$600 million** of 6.625% senior notes due 2030 and entered into new credit facilities for a **$500 million** Term Loan A and a **$600 million** Term Loan B[46](index=46&type=chunk)[49](index=49&type=chunk) Segment Performance (Three Months Ended March 31) | Segment (in thousands) | Net Revenue 2022 | Net Revenue 2021 | Operating Income 2022 | Operating Income 2021 | | :--- | :--- | :--- | :--- | :--- | | Products & Healthcare Services | $2,134,041 | $2,109,445 | $89,083 | $150,418 | | Patient Direct | $272,911 | $217,089 | $15,793 | $12,263 | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=20&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2022 performance, highlighting the Apria acquisition, segment reorganization, revenue growth driven by Patient Direct, and declining profitability due to inflationary pressures and glove pricing dynamics - The company completed the acquisition of Apria, Inc. on March 29, 2022, for approximately **$1.7 billion**, integrating it into the Patient Direct segment[88](index=88&type=chunk) - The Products & Healthcare Services segment's operating income decreased from **$150.4 million** to **$89.1 million** year-over-year, primarily due to glove price changes and accelerating inflationary pressures[89](index=89&type=chunk) - The Patient Direct segment's operating income increased from **$12.3 million** to **$15.8 million** year-over-year, driven by strong revenue growth and operating efficiencies, partially offsetting inflationary pressures[89](index=89&type=chunk) - The company is monitoring the impact of the June 2021 Philips Respironics recall, which affects the Apria business and may lead to significant costs, revenue loss, and patient hesitancy[92](index=92&type=chunk)[93](index=93&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=28&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces market risks from commodity price volatility, shipping costs, foreign currency, and interest rate changes, with a 100 basis point rate increase potentially reducing pre-tax earnings by **$9.4 million** annually - The company is exposed to price risk for raw materials like polypropylene and nitrile, as well as volatile shipping and freight costs[132](index=132&type=chunk)[134](index=134&type=chunk) - A hypothetical **100 basis point** increase in interest rates would result in a potential annual reduction in pre-tax earnings of approximately **$9.4 million**, based on debt levels at March 31, 2022[136](index=136&type=chunk) - Every **10-cent per gallon** increase in diesel fuel prices is estimated to reduce the Products & Healthcare Services segment's operating income by approximately **$0.2 million** on an annualized basis[137](index=137&type=chunk) [Controls and Procedures](index=29&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded the company's disclosure controls and procedures were effective as of March 31, 2022, excluding the newly acquired Apria, Inc. as permitted by SEC guidance - Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2022[138](index=138&type=chunk) - The evaluation of internal controls over financial reporting for the period excludes the recently acquired Apria, Inc., which represented **$2.1 billion** of total assets at the time of acquisition[139](index=139&type=chunk) Part II [Legal Proceedings](index=30&type=section&id=Item%201.%20Legal%20Proceedings) There have been no material developments in any legal proceedings since the disclosures made in the 2021 Annual Report on Form 10-K - Through March 31, 2022, there have been no material developments in any legal proceedings previously reported in the 2021 Annual Report[141](index=141&type=chunk) [Risk Factors](index=30&type=section&id=Item%201A.%20Risk%20Factors) This section updates risk factors, highlighting increased exposure to the home healthcare industry post-Apria acquisition, intense competition, reliance on limited vendors, and complex regulatory requirements including a Corporate Integrity Agreement - The acquisition of Apria has materially increased the company's exposure to risks within the highly competitive and fragmented home healthcare industry[167](index=167&type=chunk) - The company faces significant competition and pricing pressure from national, regional, and local distributors, as well as potential new entrants like large technology companies[143](index=143&type=chunk)[144](index=144&type=chunk) - The business is subject to extensive and complex healthcare laws (e.g., Anti-kickback Statute, False Claims Act, HIPAA), and the acquired Apria business must comply with a **five-year Corporate Integrity Agreement (CIA)**[152](index=152&type=chunk)[156](index=156&type=chunk)[157](index=157&type=chunk) - The company's medical gas facilities are subject to stringent FDA and state regulations, and operations involving compressed oxygen carry inherent risks of accidents[161](index=161&type=chunk)[165](index=165&type=chunk) [Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities](index=33&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities,%20Use%20of%20Proceeds%20and%20Issuer%20Purchases%20of%20Equity%20Securities) As of March 31, 2022, no shares were issued under the company's **$50.0 million** at-the-market equity financing program, leaving the full amount available - As of March 31, 2022, no shares were issued under the company's **$50.0 million** at-the-market equity financing program, leaving the full amount available[168](index=168&type=chunk) [Exhibits](index=34&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the 10-Q report, including the Apria merger agreement, new debt indentures, credit agreement amendments, and officer certifications - Key exhibits filed with this report include the merger agreement for the Apria acquisition, various debt and credit agreements, and officer certifications[169](index=169&type=chunk)[170](index=170&type=chunk)[172](index=172&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the year ended December 31, 2021 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 1-9810 OWENS & MINOR, INC. (Exact name of registrant as specified in its charter) Virginia 54-1701843 (State or other jurisdiction of incorporation or organiz ...

Owens & Minor, Inc. (NYSE:OMI) Q4 2021 Earnings Conference Call February 23, 2022 8:30 AM ET Company Participants Alex Jost - CPA Director, IR Ed Pesicka - President and CEO Andy Long - EVP and CFO Conference Call Participants Michael Cherny - Bank of America Kevin Caliendo - UBS Jailendra Singh - Credit Suisse Eric Coldwell - Baird Operator Good day and thank you for standing by. Welcome to the Owens & Minor Fourth Quarter and Full Year 2021 Earnings Conference Call. At this time, all participants are in a ...